Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006473 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00777738 | Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia(WM2) | completed | Phase 2 | 34 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 18, 2013 |
| clinicaltrials |
| NCT00005080 | 506U78 in Treating Patients With Lymphoma | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00047203 | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00058305 | Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | withdrawn | Phase 2 | 0 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00335348 | Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse | completed | Phase 2 | 101 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00022581 | Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00253578 | Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | terminated | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01761500 | Improve the Survival Rate of Chinese Children and Adolescents With Non-Hodgkin's Lymphoma | completed | Phase 2 | 200 | Sun Yat-sen UniversityOTHER | 0 | Jan 4, 2013 | clinicaltrials |
| NCT00902525 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | terminated | Phase 2 | 25 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Dec 31, 2012 | clinicaltrials |
| NCT00142181 | Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | terminated | Phase 2 | 12 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Dec 12, 2012 | clinicaltrials |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 20 | David RizzieriOTHER | 1 | Nov 28, 2012 | clinicaltrials |
| NCT00699296 | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 27, 2012 | clinicaltrials |
| NCT00882063 | Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Piramal Enterprises LimitedINDUSTRY | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00000801 | Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma | completed | Phase 2 | 33 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 1, 2012 | clinicaltrials |
| NCT00061048 | Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00168064 | Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides | completed | Phase 2 | 260 | Yaupon TherapeuticsINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00366275 | Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma | completed | Phase 2 | 64 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00742495 | Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.(BCX1777-108) | terminated | Phase 1 / Phase 2 | 2 | Mundipharma Research LimitedINDUSTRY | 6 | Oct 24, 2012 | clinicaltrials |
| NCT00012350 | Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma | completed | Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2012 | clinicaltrials |
| NCT00920855 | Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | CephalonINDUSTRY | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01054781 | Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 91 | Samsung Medical CenterOTHER | 1 | Sep 27, 2012 | clinicaltrials |
| NCT00992134 | Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma | completed | Phase 2 | 41 | St. Bortolo HospitalOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00005624 | CI-994 in Treating Patients With Advanced Myeloma | completed | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT00969085 | Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT01269203 | Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study | terminated | Phase 1 / Phase 2 | 39 | Emory UniversityOTHER | 1 | Aug 30, 2012 | clinicaltrials |
| NCT00968331 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 2 | 25 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT01036399 | Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients | terminated | Phase 2 | 9 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT00242827 | Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma | terminated | Phase 2 | — | CephalonINDUSTRY | 1 | Aug 23, 2012 | clinicaltrials |
| NCT01665014 | Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma | unknown | Phase 2 | 50 | Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, GliwiceOTHER | 1 | Aug 17, 2012 | clinicaltrials |
| NCT00240565 | Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 93 | GlaxoSmithKlineINDUSTRY | 1 | Aug 13, 2012 | clinicaltrials |
| NCT00146055 | Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | completed | Phase 2 | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00535470 | An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | completed | Phase 2 | 100 | Yaupon TherapeuticsINDUSTRY | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00772655 | Zevalin® First Line in Follicular Lymphoma | unknown | Phase 2 | 60 | Charite University, Berlin, GermanyOTHER | 0 | Aug 2, 2012 | clinicaltrials |
| NCT00067639 | Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 13 | Piramal Enterprises LimitedINDUSTRY | 2 | Jul 27, 2012 | clinicaltrials |
| NCT00303199 | Study of ZIO-101 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Alaunos TherapeuticsINDUSTRY | 2 | Jul 19, 2012 | clinicaltrials |
| NCT00051025 | Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) | completed | Phase 2 | 9 | Eisai Inc.INDUSTRY | 1 | Jul 13, 2012 | clinicaltrials |
| NCT00368121 | EMMA-1 (Erbitux for Multiple Myeloma)(EMMA-1) | terminated | Phase 2 | 13 | Prof. Dr. Andreas EngertOTHER | 1 | Jul 13, 2012 | clinicaltrials |
| NCT01538641 | Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas | completed | Phase 2 | 43 | Auxilio Mutuo Cancer CenterOTHER | 0 | Jul 13, 2012 | clinicaltrials |
| NCT00925821 | Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 146 | Wuerzburg University HospitalOTHER | 1 | Jun 28, 2012 | clinicaltrials |
| NCT00575068 | Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 42 | BiogenINDUSTRY | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00998270 | Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma | unknown | Phase 2 / Phase 3 | 185 | Tehran University of Medical SciencesOTHER | 1 | Jun 4, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2013source: clinicaltrials